In polymerase and protease drug targets and drug development, which has resulted in a strong infectious disease R&D portfolio,”and has given the company its key pipeline asset, simeprevir (TMC435), a novel protease inhibitor in Phase III clinicaldevelopment for hepatitis C that is being developed in collaboration with Janssen Pharmaceuticals. Currently, hepatitis C virus(HCV) infection is considered a serious health-care problem all over the world. A good number of direct-acting ant...